CSBR CHAMPIONS ONCOLOGY, INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 771856 · Fiscal year ends 04/30
Financial factors as of 2026-07-31 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.7%
TTM net income YoY-137.8%
TTM EPS YoY—
Revenue 3-yr CAGR4.8%
Net income 3-yr CAGR—
Margins
Gross margin49.8%
Operating margin-1.7%
Net margin-1.8%
FCF margin-10.1%
EBITDA margin0.5%
Returns
ROE-29.8%
ROA-3.5%
ROIC (approx.)—
Asset turnover1.90x
Leverage & solvency
Liabilities / assets86.6%
Debt / equity0.00x
Current ratio1.03x
Interest coverage—
Cash quality & payout
Operating cash flow / net income5.04x
Accruals ratio14.0%
Payout ratio—
Capex / revenue0.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-04-30 | FY20252025-04-30 | FY20242024-04-30 | FY20232023-04-30 | FY20222022-04-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $59.42M | $56.94M | $50.16M | $53.87M | $49.11M |
| Cost of revenue | $30.90M | $28.39M | $29.40M | $29.53M | $23.63M |
| Gross profit | $28.52M | $28.55M | $20.75M | $24.34M | $25.48M |
| R&D expense | $9.08M | $6.83M | $9.54M | $11.54M | $9.37M |
| SG&A expense | $11.15M | $9.34M | $11.07M | $10.24M | $9.12M |
| Operating income | -$1.14M | $4.55M | -$7.36M | -$5.26M | $607,000 |
| Pretax income | -$929,000 | $4.63M | -$7.31M | -$5.27M | $583,000 |
| Income tax | $246,000 | -$75,000 | -$32,000 | $68,000 | $35,000 |
| Net income | -$1.18M | $4.70M | -$7.28M | -$5.33M | $548,000 |
| EBITDA | $260,000 | $6.15M | -$5.46M | -$3.16M | $2.11M |
| EPS (basic) | -0.08 | 0.34 | -0.54 | -0.39 | 0.04 |
| EPS (diluted) | -0.08 | 0.33 | -0.54 | -0.39 | 0.04 |
| Weighted avg. shares (diluted) | 13.83M | 14.27M | 13.55M | 13.54M | 14.16M |
| Balance sheet | |||||
| Cash & equivalents | $4.87M | $9.79M | $2.62M | $10.12M | $9.01M |
| Receivables | $13.18M | $11.20M | $9.53M | $8.01M | $9.51M |
| Current assets | $19.22M | $22.36M | $13.64M | $19.46M | $19.66M |
| PP&E, net | $3.53M | $4.38M | $5.72M | $7.19M | $7.13M |
| Goodwill | $335,000 | $335,000 | $335,000 | $335,000 | $335,000 |
| Total assets | $26.99M | $32.34M | $26.13M | $34.31M | $35.38M |
| Current liabilities | $19.92M | $23.85M | $21.54M | $21.73M | $17.48M |
| Total liabilities | $22.92M | $28.57M | $28.04M | $29.68M | $26.28M |
| Shareholders' equity | $3.94M | $3.77M | -$1.90M | $4.64M | $9.10M |
| Shares outstanding | 13.89M | 13.78M | 13.59M | 13.54M | 13.52M |
| Cash flow statement | |||||
| Operating cash flow | -$4.47M | $7.39M | -$6.14M | $3.97M | $6.50M |
| Capital expenditure | $564,000 | $389,000 | $836,000 | $2.87M | $2.38M |
| Free cash flow | -$5.04M | $7.00M | -$6.97M | $1.10M | $4.11M |
| Investing cash flow | -$540,000 | -$389,000 | -$836,000 | -$2.87M | -$2.38M |
| Financing cash flow | $99,000 | $170,000 | -$527,000 | $11,000 | $207,000 |
| Depreciation & amortization | $1.40M | $1.60M | $1.90M | $2.10M | $1.50M |
| Stock-based compensation | $1.24M | $654,000 | $1.12M | $864,000 | $912,000 |
| Share buybacks | — | $0 | $634,000 | $74,000 | $0 |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.